Alpine Immune Sciences (ALPN) Revenue & Revenue Breakdown
Alpine Immune Sciences Revenue Highlights
Latest Revenue (Y)
$58.88M
Latest Revenue (Q)
$7.03M
Main Segment (Y)
Product
Main Geography (Y)
Product
Alpine Immune Sciences Revenue by Period
Alpine Immune Sciences Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $58.88M | 95.84% |
| 2022-12-31 | $30.06M | 28.24% |
| 2021-12-31 | $23.44M | 151.13% |
| 2020-12-31 | $9.34M | 436.49% |
| 2019-12-31 | $1.74M | 146.81% |
| 2018-12-31 | $705.00K | -59.27% |
| 2017-12-31 | $1.73M | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2013-12-31 | - | 100.00% |
| 2012-12-31 | - | - |
Alpine Immune Sciences generated $58.88M in revenue during NA 2023, up 95.84% compared to the previous quarter, and up 8351.21% compared to the same period a year ago.
Alpine Immune Sciences Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $7.03M | -77.21% |
| 2023-12-31 | $30.85M | 207.21% |
| 2023-09-30 | $10.04M | 16.87% |
| 2023-06-30 | $8.59M | -8.46% |
| 2023-03-31 | $9.39M | 238.15% |
| 2022-12-31 | $2.78M | -66.82% |
| 2022-09-30 | $8.37M | 58.11% |
| 2022-06-30 | $5.29M | -61.17% |
| 2022-03-31 | $13.63M | 200.86% |
| 2021-12-31 | $4.53M | -46.81% |
| 2021-09-30 | $8.52M | 18.39% |
| 2021-06-30 | $7.19M | 124.50% |
| 2021-03-31 | $3.20M | -43.22% |
| 2020-12-31 | $5.64M | 194.98% |
| 2020-09-30 | $1.91M | 178.05% |
| 2020-06-30 | $688.00K | -36.94% |
| 2020-03-31 | $1.09M | 23.42% |
| 2019-12-31 | $884.00K | 205.88% |
| 2019-09-30 | $289.00K | -49.03% |
| 2019-06-30 | $567.00K | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | -100.00% |
| 2018-06-30 | $390.00K | 23.81% |
| 2018-03-31 | $315.00K | 146.09% |
| 2017-12-31 | $128.00K | - |
| 2017-09-30 | $128.00K | -82.66% |
| 2017-06-30 | $738.00K | 0.14% |
| 2017-03-31 | $737.00K | -0.14% |
| 2016-12-31 | $738.00K | 0.14% |
| 2016-09-30 | $737.00K | 100.00% |
| 2016-06-30 | - | 100.00% |
| 2016-03-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2015-09-30 | - | 100.00% |
| 2015-06-30 | - | 100.00% |
| 2015-03-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2014-09-30 | - | 100.00% |
| 2014-06-30 | - | 100.00% |
| 2014-03-31 | - | - |
Alpine Immune Sciences generated $7.03M in revenue during Q1 2024, up -77.21% compared to the previous quarter, and up 253.31% compared to the same period a year ago.
Alpine Immune Sciences Revenue Breakdown
Alpine Immune Sciences Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 21 | Dec 20 |
|---|---|---|---|
| Product | $762.00M | $23.40M | $7.00M |
Alpine Immune Sciences's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (100.00%).
Quarterly Revenue by Product
| Product/Service | Mar 24 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Sep 19 | Jun 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Product | $337.50M | $4.50M | $8.50M | $7.20M | $3.20M | $5.40M | $356.00K | $602.00K | $1.10M | $288.00K | $142.00K |
Alpine Immune Sciences's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Product (100.00%).
Alpine Immune Sciences Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 21 | Dec 20 |
|---|---|---|
| Product | $23.40M | $7.00M |
Alpine Immune Sciences's latest annual revenue breakdown by geography, as of Dec 21: Product (100.00%).
Quarterly Revenue by Country
| Country | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Sep 19 | Jun 19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Product | $4.50M | $8.50M | $7.20M | $3.20M | $5.40M | $356.00K | $602.00K | $1.10M | $288.00K | $142.00K |
Alpine Immune Sciences's latest quarterly revenue breakdown by geography, as of Dec 21: Product (100.00%).
Alpine Immune Sciences Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| AMLX | Amylyx Pharmaceuticals | $380.79M | $88.64M |
| ALPN | Alpine Immune Sciences | $58.88M | $7.03M |
| BCYC | Bicycle Therapeutics | $26.98M | $9.36M |
| ADAG | Adagene | $18.11M | $833.34K |
| ANAB | AnaptysBio | $17.16M | $10.97M |
| STOK | Stoke Therapeutics | $8.78M | $4.22M |
| IGMS | IGM Biosciences | $2.13M | $497.00K |
| ANEB | Anebulo Pharmaceuticals | - | - |
| DAWN | Day One Biopharmaceuticals | - | $8.19M |
| ABOS | Acumen Pharmaceuticals | - | - |
| TERN | Terns Pharmaceuticals | - | - |
| ACRV | Acrivon Therapeutics | - | - |
| MLYS | Mineralys Therapeutics | - | - |
| GLUE | Monte Rosa Therapeutics | - | $4.70M |
| MLTX | MoonLake Immunotherapeutics | - | - |
| TNYA | Tenaya Therapeutics | - | - |
ALPN Revenue FAQ
What is Alpine Immune Sciences’s yearly revenue?
Alpine Immune Sciences's yearly revenue for 2023 was $58.88M, representing an increase of 95.84% compared to 2022. The company's yearly revenue for 2022 was $30.06M, representing an increase of 28.24% compared to 2021. ALPN's yearly revenue for 2021 was $23.44M, representing an increase of 151.13% compared to 2020.
What is Alpine Immune Sciences’s quarterly revenue?
Alpine Immune Sciences's quarterly revenue for Q1 2024 was $7.03M, a -77.21% decrease from the previous quarter (Q4 2023), and a -25.09% decrease year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $30.85M, a 207.21% increase from the previous quarter (Q3 2023), and a 1011.42% increase year-over-year (Q4 2022). ALPN's quarterly revenue for Q3 2023 was $10.04M, a 16.87% increase from the previous quarter (Q2 2023), and a 20.03% increase year-over-year (Q3 2022).
What is Alpine Immune Sciences’s revenue growth rate?
Alpine Immune Sciences's revenue growth rate for the last 3 years (2021-2023) was 151.15%, and for the last 5 years (2019-2023) was 3283.68%.
What are Alpine Immune Sciences’s revenue streams?
Alpine Immune Sciences's revenue streams in c 23 are Product
What is Alpine Immune Sciences’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Alpine Immune Sciences was Product. This segment made a revenue of $762M, representing 100.00% of the company's total revenue.